BACKGROUND: Recent discoveries of risk alleles have made it possible to define genetic risk profiles for patients with rheumatoid arthritis (RA). This study examined whether a cumulative score based on 22 validated genetic risk alleles for seropositive RA would identify high-risk, asymptomatic individuals who might benefit from preventive interventions. METHODS: Eight human leucocyte antigen (HLA) alleles and 14 single-nucleotide polymorphisms representing 13 validated RA risk loci were genotyped among 289 white seropositive cases and 481 controls from the US Nurses' Health Studies (NHS) and 629 white cyclic-citrullinated peptide antibody-positive cases and 623 controls from the Swedish Epidemiologic Investigation of Rheumatoid Arthritis (EIRA). A weighted genetic risk score (GRS) was created, in which the weight for each risk allele is the log of the published odds ratio (OR). Logistic regression was used to study associations with incident RA. Area under the curve (AUC) statistics were compared from a clinical-only model and clinical plus genetic model in each cohort. RESULTS: Patients with GRS >1.25 SD of the mean had a significantly higher OR of seropositive RA in both NHS (OR=2.9, 95%CI 1.8 to 4.6) and EIRA (OR 3.4, 95% CI 2.3 to 5.0) referent to the population average. In NHS, the AUC for a clinical model was 0.57 and for a clinical plus genetic model was 0.66, and in EIRA was 0.63 and 0.75, respectively. CONCLUSION: The combination of 22 risk alleles into a weighted GRS significantly stratifies individuals for RA risk beyond clinical risk factors alone. Given the low incidence of RA, the clinical utility of a weighted GRS is limited in the general population.
BACKGROUND: Recent discoveries of risk alleles have made it possible to define genetic risk profiles for patients with rheumatoid arthritis (RA). This study examined whether a cumulative score based on 22 validated genetic risk alleles for seropositive RA would identify high-risk, asymptomatic individuals who might benefit from preventive interventions. METHODS: Eight human leucocyte antigen (HLA) alleles and 14 single-nucleotide polymorphisms representing 13 validated RA risk loci were genotyped among 289 white seropositive cases and 481 controls from the US Nurses' Health Studies (NHS) and 629 white cyclic-citrullinated peptide antibody-positive cases and 623 controls from the Swedish Epidemiologic Investigation of Rheumatoid Arthritis (EIRA). A weighted genetic risk score (GRS) was created, in which the weight for each risk allele is the log of the published odds ratio (OR). Logistic regression was used to study associations with incident RA. Area under the curve (AUC) statistics were compared from a clinical-only model and clinical plus genetic model in each cohort. RESULTS:Patients with GRS >1.25 SD of the mean had a significantly higher OR of seropositive RA in both NHS (OR=2.9, 95%CI 1.8 to 4.6) and EIRA (OR 3.4, 95% CI 2.3 to 5.0) referent to the population average. In NHS, the AUC for a clinical model was 0.57 and for a clinical plus genetic model was 0.66, and in EIRA was 0.63 and 0.75, respectively. CONCLUSION: The combination of 22 risk alleles into a weighted GRS significantly stratifies individuals for RA risk beyond clinical risk factors alone. Given the low incidence of RA, the clinical utility of a weighted GRS is limited in the general population.
Authors: Sekar Kathiresan; Olle Melander; Dragi Anevski; Candace Guiducci; Noël P Burtt; Charlotta Roos; Joel N Hirschhorn; Göran Berglund; Bo Hedblad; Leif Groop; David M Altshuler; Christopher Newton-Cheh; Marju Orho-Melander Journal: N Engl J Med Date: 2008-03-20 Impact factor: 91.245
Authors: Annette H M van der Helm-van Mil; Jacqueline Detert; Saskia le Cessie; Andrew Filer; Hans Bastian; Gerd R Burmester; Tom W J Huizinga; Karim Raza Journal: Arthritis Rheum Date: 2008-08
Authors: Guillaume Lettre; Anne U Jackson; Christian Gieger; Fredrick R Schumacher; Sonja I Berndt; Serena Sanna; Susana Eyheramendy; Benjamin F Voight; Johannah L Butler; Candace Guiducci; Thomas Illig; Rachel Hackett; Iris M Heid; Kevin B Jacobs; Valeriya Lyssenko; Manuela Uda; Michael Boehnke; Stephen J Chanock; Leif C Groop; Frank B Hu; Bo Isomaa; Peter Kraft; Leena Peltonen; Veikko Salomaa; David Schlessinger; David J Hunter; Richard B Hayes; Gonçalo R Abecasis; H-Erich Wichmann; Karen L Mohlke; Joel N Hirschhorn Journal: Nat Genet Date: 2008-04-06 Impact factor: 38.330
Authors: Michael N Weedon; Hana Lango; Cecilia M Lindgren; Chris Wallace; David M Evans; Massimo Mangino; Rachel M Freathy; John R B Perry; Suzanne Stevens; Alistair S Hall; Nilesh J Samani; Beverly Shields; Inga Prokopenko; Martin Farrall; Anna Dominiczak; Toby Johnson; Sven Bergmann; Jacques S Beckmann; Peter Vollenweider; Dawn M Waterworth; Vincent Mooser; Colin N A Palmer; Andrew D Morris; Willem H Ouwehand; Jing Hua Zhao; Shengxu Li; Ruth J F Loos; Inês Barroso; Panagiotis Deloukas; Manjinder S Sandhu; Eleanor Wheeler; Nicole Soranzo; Michael Inouye; Nicholas J Wareham; Mark Caulfield; Patricia B Munroe; Andrew T Hattersley; Mark I McCarthy; Timothy M Frayling Journal: Nat Genet Date: 2008-04-06 Impact factor: 38.330
Authors: Soumya Raychaudhuri; Elaine F Remmers; Annette T Lee; Rachel Hackett; Candace Guiducci; Noël P Burtt; Lauren Gianniny; Benjamin D Korman; Leonid Padyukov; Fina A S Kurreeman; Monica Chang; Joseph J Catanese; Bo Ding; Sandra Wong; Annette H M van der Helm-van Mil; Benjamin M Neale; Jonathan Coblyn; Jing Cui; Paul P Tak; Gert Jan Wolbink; J Bart A Crusius; Irene E van der Horst-Bruinsma; Lindsey A Criswell; Christopher I Amos; Michael F Seldin; Daniel L Kastner; Kristin G Ardlie; Lars Alfredsson; Karen H Costenbader; David Altshuler; Tom W J Huizinga; Nancy A Shadick; Michael E Weinblatt; Niek de Vries; Jane Worthington; Mark Seielstad; Rene E M Toes; Elizabeth W Karlson; Ann B Begovich; Lars Klareskog; Peter K Gregersen; Mark J Daly; Robert M Plenge Journal: Nat Genet Date: 2008-09-14 Impact factor: 38.330
Authors: Michelle M A Fernando; Christine R Stevens; Emily C Walsh; Philip L De Jager; Philippe Goyette; Robert M Plenge; Timothy J Vyse; John D Rioux Journal: PLoS Genet Date: 2008-04-25 Impact factor: 5.917
Authors: Karen H Costenbader; Shun-Chiao Chang; Immaculata De Vivo; Robert Plenge; Elizabeth W Karlson Journal: Arthritis Res Ther Date: 2008-05-07 Impact factor: 5.156
Authors: Anne Barton; Wendy Thomson; Xiayi Ke; Steve Eyre; Anne Hinks; John Bowes; Darren Plant; Laura J Gibbons; Anthony G Wilson; Deborah E Bax; Ann W Morgan; Paul Emery; Sophia Steer; Lynne Hocking; David M Reid; Paul Wordsworth; Pille Harrison; Jane Worthington Journal: Nat Genet Date: 2008-09-14 Impact factor: 38.330
Authors: Hugues Aschard; Jinbo Chen; Marilyn C Cornelis; Lori B Chibnik; Elizabeth W Karlson; Peter Kraft Journal: Am J Hum Genet Date: 2012-05-24 Impact factor: 11.025
Authors: Jeffrey A Sparks; Chia-Yen Chen; Xia Jiang; Johan Askling; Linda T Hiraki; Susan Malspeis; Lars Klareskog; Lars Alfredsson; Karen H Costenbader; Elizabeth W Karlson Journal: Ann Rheum Dis Date: 2014-03-31 Impact factor: 19.103
Authors: Zoe H Brett; Margaret Sheridan; Kate Humphreys; Anna Smyke; Mary Margaret Gleason; Nathan Fox; Charles Zeanah; Charles Nelson; Stacy Drury Journal: Int J Behav Dev Date: 2015-03
Authors: Sampath Prahalad; Karen N Conneely; Yunxuan Jiang; Marc Sudman; Carol A Wallace; Milton R Brown; Lori A Ponder; Mina Rohani-Pichavant; Michael E Zwick; David J Cutler; Sheila T Angeles-Han; Larry B Vogler; Christine Kennedy; Kelly Rouster-Stevens; Carol A Wise; Marilynn Punaro; Ann M Reed; Elizabeth D Mellins; John F Bohnsack; David N Glass; Susan D Thompson Journal: Arthritis Rheum Date: 2013-06
Authors: Elizabeth W Karlson; Bo Ding; Brendan T Keenan; Katherine Liao; Karen H Costenbader; Lars Klareskog; Lars Alfredsson; Lori B Chibnik Journal: Arthritis Care Res (Hoboken) Date: 2013-07 Impact factor: 4.794
Authors: Elizabeth W Karlson; Dirkjan van Schaardenburg; Annette H van der Helm-van Mil Journal: Rheumatology (Oxford) Date: 2014-08-04 Impact factor: 7.580